Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
3.470
+0.060 (1.76%)
At close: Feb 21, 2025, 4:00 PM
3.310
-0.160 (-4.61%)
After-hours: Feb 21, 2025, 5:57 PM EST
Aptevo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 3.11 | 12.29 | 4.31 | |
| Revenue Growth (YoY) | - | - | -74.67% | 185.26% | - | |
| Cost of Revenue | 0.3 | 0.68 | 17.88 | 18.99 | 17.85 | |
| Gross Profit | -0.3 | -0.68 | -14.77 | -6.7 | -13.54 | |
| Selling, General & Admin | 10.22 | 11.77 | 13.87 | 14.7 | 13.95 | |
| Research & Development | 14.08 | 16.42 | - | - | - | |
| Operating Expenses | 24.3 | 28.19 | 13.87 | 14.7 | 13.95 | |
| Operating Income | -24.6 | -28.88 | -28.64 | -21.4 | -27.49 | |
| Other Non Operating Income (Expenses) | 0.47 | 0.58 | -1.53 | -8.01 | -1.33 | |
| EBT Excluding Unusual Items | -24.13 | -28.3 | -30.17 | -29.41 | -28.82 | |
| Gain (Loss) on Sale of Assets | - | 9.65 | - | - | - | |
| Other Unusual Items | - | - | 37.18 | - | -2.1 | |
| Pretax Income | -24.13 | -18.65 | 7.01 | -29.41 | -30.92 | |
| Earnings From Continuing Operations | -24.13 | -18.65 | 7.01 | -29.41 | -30.92 | |
| Earnings From Discontinued Operations | - | 1.24 | 1.01 | 0.95 | 13.17 | |
| Net Income | -24.13 | -17.41 | 8.03 | -28.46 | -17.75 | |
| Net Income to Common | -24.13 | -17.41 | 8.03 | -28.46 | -17.75 | |
| Shares Outstanding (Basic) | 0 | - | - | - | - | |
| Shares Outstanding (Diluted) | 0 | - | - | - | - | |
| EPS (Basic) | -87.38 | - | - | - | - | |
| EPS (Diluted) | -87.38 | - | - | - | - | |
| Free Cash Flow | -23.79 | -11.73 | -21.05 | -22.39 | -29.41 | |
| Free Cash Flow Per Share | -86.13 | - | - | - | - | |
| Gross Margin | - | - | - | -54.52% | - | |
| Operating Margin | - | - | -919.75% | -174.10% | -638.06% | |
| Profit Margin | - | - | 257.77% | -231.51% | -411.93% | |
| Free Cash Flow Margin | - | - | -676.01% | -182.17% | -682.43% | |
| EBITDA | -24.25 | -28.31 | -27.74 | -20.26 | -26.19 | |
| EBITDA Margin | - | - | - | -164.79% | - | |
| D&A For EBITDA | 0.35 | 0.57 | 0.9 | 1.14 | 1.31 | |
| EBIT | -24.6 | -28.88 | -28.64 | -21.4 | -27.49 | |
| EBIT Margin | - | - | - | -174.10% | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.